2442 related articles for article (PubMed ID: 27235694)
1. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
2. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
Furness AJ; Quezada SA; Peggs KS
Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
[No Abstract] [Full Text] [Related]
3. Introduction: Cancer Immunology Special Issue-Immunotherapy.
Kawakami Y
Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
[No Abstract] [Full Text] [Related]
4. The role of neoantigens in response to immune checkpoint blockade.
Riaz N; Morris L; Havel JJ; Makarov V; Desrichard A; Chan TA
Int Immunol; 2016 Aug; 28(8):411-9. PubMed ID: 27048318
[TBL] [Abstract][Full Text] [Related]
5. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
[TBL] [Abstract][Full Text] [Related]
6. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
7. Targeting neoantigens for cancer immunotherapy.
Lu YC; Robbins PF
Int Immunol; 2016 Jul; 28(7):365-70. PubMed ID: 27208041
[TBL] [Abstract][Full Text] [Related]
8. 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.
Tran E; Robbins PF; Rosenberg SA
Nat Immunol; 2017 Feb; 18(3):255-262. PubMed ID: 28198830
[TBL] [Abstract][Full Text] [Related]
9. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
10. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
11. [Not Available].
Depil S; Bonaventura P; Alcazer V; Tonon L
Bull Cancer; 2018 Dec; 105 Suppl 1():S113-S120. PubMed ID: 30595192
[TBL] [Abstract][Full Text] [Related]
12. Colorectal cancer vaccines: Tumor-associated antigens
Wagner S; Mullins CS; Linnebacher M
World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
[TBL] [Abstract][Full Text] [Related]
13. [Era of cancer immunotherapy has come].
Nakatsura T
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):164-71. PubMed ID: 27320931
[TBL] [Abstract][Full Text] [Related]
14. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
Antonia SJ; Vansteenkiste JF; Moon E
Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
[TBL] [Abstract][Full Text] [Related]
16. PD-1/PD-L1 in disease.
Kuol N; Stojanovska L; Nurgali K; Apostolopoulos V
Immunotherapy; 2018 Feb; 10(2):149-160. PubMed ID: 29260623
[TBL] [Abstract][Full Text] [Related]
17. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.
de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M
Front Immunol; 2021; 12():592031. PubMed ID: 34335558
[TBL] [Abstract][Full Text] [Related]
18. Coinhibitory Pathways in Immunotherapy for Cancer.
Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
[TBL] [Abstract][Full Text] [Related]
19. Advances in personalized neoantigen vaccines for cancer immunotherapy.
Sun C; Xu S
Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]